Compare PRGO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | NUVB |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | 305 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2020 |
| Metric | PRGO | NUVB |
|---|---|---|
| Price | $16.09 | $4.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $16.50 | $13.00 |
| AVG Volume (30 Days) | 2.7M | ★ 5.0M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | N/A | ★ N/A |
| Revenue | $800,000.00 | ★ $62,902,000.00 |
| Revenue This Year | N/A | $211.79 |
| Revenue Next Year | $0.74 | $45.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $9.23 | $3.92 |
| 52 Week High | $22.01 | $9.75 |
| Indicator | PRGO | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 33.93 |
| Support Level | $13.55 | $4.10 |
| Resistance Level | N/A | $5.16 |
| Average True Range (ATR) | 0.66 | 0.24 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 75.87 | 33.57 |
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.